Cardiol Therapeutics Inc.
CRDL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001702123
No open-market purchases or sales by Cardiol Therapeutics Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $31.3M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Cardiol Therapeutics Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 38 | 38 | 0 |
| Shares | 7.72M | 6.47M | −1.25M (−16.2%) |
| Value | $7.44M | $8.80M | +$1.36M (+18.3%) |
New holders (7)
Institutions that held Cardiol Therapeutics Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mercer Global Advisors Inc | 22,600 | $30.7K | 0.00% |
| Susquehanna International Group, LLP | 20,023 | $27.2K | 0.00% |
| Wealth Enhancement Advisory Services, LLC | 16,840 | $25.9K | 0.00% |
| LPL Financial LLC | 15,210 | $20.7K | 0.00% |
| MONECO Advisors, LLC | 15,000 | $20.4K | 0.00% |
| Janney Montgomery Scott LLC | 14,200 | $19.0K | 0.00% |
| Raymond James Financial Inc | 6,154 | $8.37K | 0.00% |
Sold out (7)
Institutions that held Cardiol Therapeutics Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| UBS Asset Management Americas Inc | 55,000 | $53.4K |
| Virtu Financial LLC | 16,038 | $16.0K |
| Evelyn Partners Investment Management LLP | 10,000 | $9.52K |
| Hartford Financial Management Inc. | 4,000 | $3.88K |
| Tower Research Capital LLC (TRC) | 118 | $114 |
| Stone House Investment Management, LLC | 50 | $48 |
| Wells Fargo & Company | 25 | $24 |